Average obligated amount per year since period start.
Portion of total contract value already obligated.
Share of total value represented by subawards.
PHASE I STUDY OF THE INFECTIVITY, SAFETY AND IMMUNOGENICITY OF A RECOMBINANT, LIVE-ATTENUATED, BOVINE/HUMAN, PARAINFLUENZA VIRUS TYPE 3 (B/HPIV3) VECTOR VACCINE EXPRESSING THE SPIKE GLYCOPROTEIN OF SARS-COV-2, DELIVERED BY NASAL SPRAY TO HPIV3-SEROPO
Task order obligations
Estimated months remaining until end of performance.
Period of performance
100% of period elapsed
Awarding Agency
NINATIONAL INSTITUTES OF HEALTH
Code: 7529
Funding Agency
NINATIONAL INSTITUTES OF HEALTH
Code: 7529
Loading contract activity data...
Modification ID | Description | Action Date | Obligated Amount | Action Type |
|---|---|---|---|---|
Subaward # | Subawardee | Description | Amount | Action Date |
|---|---|---|---|---|